Estimating the effectiveness of non-pharmaceutical interventions against COVID-19 transmission in the Netherlands.

Estimating the effectiveness of non-pharmaceutical interventions against COVID-19 transmission in the Netherlands.

Publication date: Sep 17, 2025

During the COVID-19 pandemic non-pharmaceutical interventions (NPIs) were taken to mitigate virus spread. Assessing their effectiveness is essential in policy support but often challenging, due to interactions between measures, the increase of immunity, variant emergence and seasonal effects. These factors make results difficult to interpret over a long period of time. Using a mechanistic approach, we estimate the overall effectiveness of sets of NPIs in reducing transmission over time. Our approach quantifies the effectiveness by comparing the observed effective reproduction number, which is the number of secondary infections caused by a typical infected person, to a counterfactual reproduction number if no NPIs were taken. The counterfactual reproduction number accounts for seasonal variations in transmissibility, for emergence of more transmissible variants, and for changes in immunity in the population. The immune fraction is reconstructed from age-specific data of longitudinal serological surveys and vaccination coverage, taking immunity loss due to waning into account. We estimate the effectiveness of NPIs in the Netherlands from the start of the pandemic in March 2020 until the emergence of the Omicron variant in November 2021. We find that the effectiveness of NPIs was high in March and April 2020 during the first pandemic wave and in January and February 2021, coinciding with the two periods with the most stringent measures. For both periods the effectiveness was estimated at approximately 50%, i. e., without any measures the reproduction number would have been twice as high as observed. The proposed approach synthesises available epidemiological data from different sources to reconstruct the population-level immunity. With sufficient data, it can be applied not only to COVID-19 but also to other directly transmitted diseases, such as influenza. This method provides a near real-time assessment of the effectiveness of control measures when the required data are available.

Open Access PDF

Concepts Keywords
Effectiveness Covid
Netherlands Effectiveness
Pandemic Emergence
Vaccination Immunity
Interventions
Measures
Netherlands
Non
Npis
Pandemic
Pharmaceutical
Reproduction
Time
Transmission
Variant

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME Reproduction
disease MESH secondary infections
disease MESH influenza
disease IDO history
disease IDO process
drug DRUGBANK Naproxen
drug DRUGBANK Cysteamine
disease MESH infections
disease IDO intervention
disease IDO immune population
drug DRUGBANK Coenzyme M
disease MESH uncertainty
disease IDO infection
disease IDO susceptible population
drug DRUGBANK Aspartame
disease IDO infection incidence
disease MESH reinfections
disease MESH breakthrough infections
drug DRUGBANK Albendazole
disease IDO role
disease IDO susceptibility
disease IDO country
disease MESH infectious diseases
disease MESH respiratory infections
disease MESH sexually transmitted infections
drug DRUGBANK Isoxaflutole
drug DRUGBANK L-Valine
disease IDO symptom
disease IDO primary infection
disease MESH person to person transmission
drug DRUGBANK Guanosine
drug DRUGBANK Medical air
disease MESH asymptomatic infection
disease MESH Pneumonia
disease IDO contact tracing
disease MESH viral load
disease MESH Loneliness
drug DRUGBANK Cefalotin

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *